ํBOT โข ASX
add
Botanix Pharmaceuticals Ltd
์ ์ผ ์ข
๊ฐ
$0.14
์ผ์ผ ๋ณ๋ํญ
$0.13 - $0.14
52์ฃผ ๋ณ๋ํญ
$0.10 - $0.54
์๊ฐ์ด์ก
2.47์ต AUD
ํ๊ท ๊ฑฐ๋๋
496.13๋ง
์ฃผ๊ฐ์์ต๋ฅ
-
๋ฐฐ๋น์์ต๋ฅ
-
๊ธฐ๋ณธ ๊ฑฐ๋์
ASX
์์ฅ ๋ด์ค
์ฌ๋ฌด
์์ต๊ณ์ฐ์
์์ต
์์ด์ต
| (AUD) | 2025๋ 6์info | ์ ๋ ๋๋น ๋ณ๋ |
|---|---|---|
์์ต | 270.58๋ง | 219.92% |
์ด์๋น | 2689.60๋ง | 618.83% |
์์ด์ต | -2775.40๋ง | -560.61% |
์์ด์ต๋ฅ | -1.03์ฒ | -106.50% |
์ฃผ๋น ์์ต | โ | โ |
EBITDA | -2489.88๋ง | -492.72% |
์ ํจ ์ธ์จ | โ | โ |
๋์ฐจ๋์กฐํ
์ด์์ฐ
์ด๋ถ์ฑ
| (AUD) | 2025๋ 6์info | ์ ๋ ๋๋น ๋ณ๋ |
|---|---|---|
ํ๊ธ ๋ฐ ๋จ๊ธฐ ํฌ์ | 6496.66๋ง | -18.08% |
์ด์์ฐ | 1.29์ต | 14.79% |
์ด๋ถ์ฑ | 4779.64๋ง | 1,180.69% |
์ด์๊ธฐ์๋ณธ | 8129.89๋ง | โ |
๋ฐํ ์ฃผ์ | 19.61์ต | โ |
์ฃผ๊ฐ์์์ฐ๋น์จ | 3.38 | โ |
์ด์์ฐ์ด์ต๋ฅ | -49.33% | โ |
์๋ณธ์ด์ต๋ฅ | -77.17% | โ |
ํ๊ธ ํ๋ฆ
์ํ๊ธํ๋ฆ
| (AUD) | 2025๋ 6์info | ์ ๋ ๋๋น ๋ณ๋ |
|---|---|---|
์์ด์ต | -2775.40๋ง | -560.61% |
์์
ํ๊ธ ํ๋ฆ | -2401.16๋ง | -999.67% |
ํฌ์ ํ๊ธ ํ๋ฆ | -9.80๋ง | 93.92% |
์๊ธ ์กฐ๋ฌ ํ๊ธ ํ๋ฆ | 3247.83๋ง | -4.95% |
์ํ๊ธํ๋ฆ | 826.49๋ง | -72.90% |
์์ฌ ํ๊ธ ํ๋ฆ | -959.42๋ง | -245.54% |
์ ๋ณด
Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic cannabinoid company, focusing on the compound Cannabidiol. The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex, for direct skin delivery of active pharmaceuticals which is utilised in all of their programs. Wikipedia
์ค๋ฆฝ
1984
์น์ฌ์ดํธ
์ง์ ์
11